Since its entry into China, Sumitomo Pharma (Suzhou) Co., Ltd. has worked in three major fields: central nervous system disorders, anti-infection, and cardiovascular diseases. The company has been relieving the suffering of Chinese patients and benefiting them for more than two decades. Further, Sumitomo Pharma (Suzhou) Co., Ltd. understands its responsibility as a pharmaceutical company and hopes to use its expertise to bring a profound impact on the industry's innovation, research, and development.
Making the company a "professional global company" that is capable of meeting the increasingly diversified healthcare needs.
Brand name/Product code
(Generic name)Lefamulin, a pleuromutilin antibiotic developed by Nabriva Therapeutics Ireland Designated Activity Company (headquartered in Dublin, Ireland), has a different mechanism of action from that of existing antibiotics. It is a new anti-infective drug that is less likely to develop resistance and cross-resistance. The drug has been approved by the U.S. Food and Drug Administration (FDA), Health Canada, and the European Medicines Agency (EMA) for the treatment of community-acquired bacterial pneumonia in adults and is currently marketed under the name "XENLETA" in the United States. Lefamulin is one of the four new products that Sumitomo Pharma (Suzhou) Co., Ltd. announced in May this year with exclusive development and sales rights in mainland China, Hong Kong China, and Taiwan China.
According to the Provisions on the Administration of Pharmaceutical Directions and Labels (decree No. 24 of the National Medical Products Administration), after the approval of the revision of drug instructions, drug manufacturers should immediately notify the relevant pharmaceutical trading enterprises, user units, and other departments of the revised content. The company publishes the latest approved specifications as required by the regulations to enable relevant units and medical and health professionals to obtain the latest information timely. The following is only available to health care professionals.
You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.
You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.
